Choosing Less: Medication and Active Monitoring
At a Glance
For selected low-risk, estrogen-sensitive DCIS, medication after surgery can lower the chance of another breast event. Active monitoring is not routine care yet because a biopsy may miss nearby invasive cancer and long-term safety remains uncertain.
For many years, the standard treatment for DCIS was surgery for everyone. Today, however, doctors and patients are exploring ways to tailor treatment to the actual risk of the disease. Two major strategies for reducing “overtreatment” while still managing risk are endocrine therapy (medication) and active surveillance (closely monitoring the lesion) [1][2].
Endocrine Therapy: Reducing the Risk of Future Events
If your DCIS is Estrogen Receptor-positive (ER+), your cells use estrogen to grow. Endocrine therapy uses medication to block this estrogen [3].
It is important to know that these drugs do not replace surgical excision of established DCIS. They are an adjuvant (add-on) risk-reduction strategy used after a lumpectomy. While they significantly lower the relative chance of the disease returning or a new cancer developing in either breast, they have no proven benefit on overall survival [4][5].
Commonly used medications include:
- Tamoxifen: Often used for both pre- and post-menopausal women. In relevant trials, it reduced the relative risk of a new breast event by 30% to 50% [4][6].
- Aromatase Inhibitors (AIs): Such as anastrozole, used only for post-menopausal women. They are broadly comparable to tamoxifen for risk reduction in this group [7][5].
The choice between these drugs depends on your menopausal status and side effect profile. Tamoxifen is associated with hot flashes and, rarely, a higher risk of blood clots or uterine cancer [5][8]. Aromatase inhibitors do not carry those specific risks but can cause joint pain, bone thinning (osteoporosis), and higher cholesterol [5][9]. Endocrine therapy after a mastectomy often offers little absolute benefit and its use is highly individualized.
Active Surveillance: Is Surgery Always Necessary?
Active surveillance (or active monitoring) is an investigational approach for highly selected “low-risk” DCIS. This is generally defined as DCIS that is Grade 1 or 2, ER-positive, and caught only on a screening mammogram without a palpable mass [2][10].
Eligibility is strict, and surveillance is not simply “watchful waiting” at home. It must occur through a structured specialist program or clinical trial (like the COMET, LORIS, or LORD trials) with predefined triggers for surgery [11][12].
Early results from the COMET trial met a short-term noninferiority criterion: at two years, the cumulative risk of ipsilateral invasive cancer was approximately 5.9% with active monitoring versus 4.2% with guideline-concordant care [2]. However, two-year data cannot establish long-term equivalence or safety, so active monitoring is not yet a routine standard of care.
The Catch: Hidden Invasive Cancer (Occult Invasion)
The biggest challenge with choosing surveillance over surgery is the limit of the initial biopsy. A core needle biopsy only takes a tiny sample. It is possible for the biopsy to show only DCIS, while a small area of invasive cancer is hiding nearby [13][14].
This is known as occult invasion or an upgrade. When patients with trial-eligible “low-risk” DCIS choose to have surgery, researchers find an upgrade rate of 5% to 12% [15][16]. Finding an invasive focus does not automatically mean it would have required more intensive treatment or changed survival, but it alters the final pathology and subsequent management plan [17][18].
Risk factors that make an upgrade more likely include an extensive lesion size, higher grades, or a mass seen on ultrasound [19][14]. For many, the uncertainty of this “upgrade risk” is the deciding factor in choosing surgery over surveillance.
Common questions in this guide
Can medication replace surgery for DCIS?
Who may be considered for active surveillance instead of immediate surgery?
How often does surgery reveal invasive cancer after a biopsy shows low-risk DCIS?
What is the difference between tamoxifen and anastrozole for DCIS?
Does endocrine therapy improve survival in DCIS?
What happens if active monitoring shows a change?
One line in your results can change your plan.
An invasive focus found on final pathology can alter the management plan, so ask your doctor what it would mean. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on ductal breast carcinoma in situ.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
Advancements in Detection and Management of Ductal Carcinoma in Situ.
Tucunduva TCM, Zanetta VC, Chala LF, et al.
Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(9)):e240174 doi:10.1148/rg.240174.
PMID: 40773373 - 2
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.
Hwang ES, Hyslop T, Lynch T, et al.
JAMA 2025; (333(11)):972-980 doi:10.1001/jama.2024.26698.
PMID: 39665585 - 3
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.
Allison KH, Hammond MEH, Dowsett M, et al.
Archives of pathology & laboratory medicine 2020; (144(5)):545-563 doi:10.5858/arpa.2019-0904-SA.
PMID: 31928354 - 4
The effects of adjuvant endocrine therapy on long-term outcomes from ductal carcinoma in situ: a systematic review and meta-analysis.
Chen Q, Campbell I, Elwood M, et al.
Breast (Edinburgh, Scotland) 2025; (82()):104521 doi:10.1016/j.breast.2025.104521.
PMID: 40540939 - 5
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Forbes JF, Sestak I, Howell A, et al.
Lancet (London, England) 2016; (387(10021)):866-73.
PMID: 26686313 - 6
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(19)):1629-1637 doi:10.1200/JCO.18.01779.
PMID: 30973790 - 7
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG, Cecchini RS, Julian TB, et al.
Lancet (London, England) 2016; (387(10021)):849-56.
PMID: 26686957 - 8
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Ganz PA, Cecchini RS, Julian TB, et al.
Lancet (London, England) 2016; (387(10021)):857-65.
PMID: 26686960 - 9
Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
Yan Y, Zhang L, Tan L, et al.
Pathology oncology research : POR 2020; (26(1)):521-531 doi:10.1007/s12253-018-0553-y.
PMID: 30499075 - 10
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
Elshof LE, Tryfonidis K, Slaets L, et al.
European journal of cancer (Oxford, England : 1990) 2015; (51(12)):1497-510.
PMID: 26025767 - 11
The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).
Hwang ES, Hyslop T, Lynch T, et al.
BMJ open 2019; (9(3)):e026797 doi:10.1136/bmjopen-2018-026797.
PMID: 30862637 - 12
Recruiting women with ductal carcinoma in situ to a randomised controlled trial: lessons from the LORIS study.
Wheelwright S, Matthews L, Jenkins V, et al.
Trials 2023; (24(1)):670 doi:10.1186/s13063-023-07703-4.
PMID: 37838682 - 13
Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M, Stempel M, Rosenfeld H, et al.
Annals of surgical oncology 2016; (23(11)):3487-3493 doi:10.1245/s10434-016-5268-2.
PMID: 27172775 - 14
Calcification and tumour-infiltrating lymphocytes predict upgrade of human epidermal growth factor 2 (HER2)-negative ductal carcinoma in situ diagnosed on core needle biopsy.
Marabi M, Li Y, Aphivatanasiri C, et al.
Histopathology 2026; (89(1)):122-135 doi:10.1111/his.70143.
PMID: 41905345 - 15
Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?
Oseni TO, Smith BL, Lehman CD, et al.
Annals of surgical oncology 2020; (27(11)):4459-4465 doi:10.1245/s10434-020-08576-6.
PMID: 32418079 - 16
Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials.
Grimm LJ, Ryser MD, Partridge AH, et al.
Annals of surgical oncology 2017; (24(12)):3534-3540 doi:10.1245/s10434-017-6018-9.
PMID: 28795370 - 17
Proportion of Patients With Ductal Carcinoma In Situ That Qualify for Observation Criteria Set Forth by Clinical Trials.
McAdams CD, Clevenger N, Nicholson K, et al.
Journal of surgical oncology 2025; (131(2)):115-123 doi:10.1002/jso.27858.
PMID: 39295556 - 18
A Model to Predict Upstaging to Invasive Carcinoma in Patients Preoperatively Diagnosed with Low-Grade Ductal Carcinoma In Situ of the Breast.
Nicosia L, Bozzini AC, Penco S, et al.
Cancers 2022; (14(2)) doi:10.3390/cancers14020370.
PMID: 35053533 - 19
Precise application of sentinel lymph node biopsy in patients with ductal carcinoma in situ: A systematic review and meta-analysis of real-world data.
Chiu CW, Chang LC, Su CM, et al.
Surgical oncology 2022; (45()):101880 doi:10.1016/j.suronc.2022.101880.
PMID: 36332555
This page is for informational purposes only and does not constitute medical advice. Discuss DCIS surveillance, surgery, and endocrine therapy with your breast care team, who can interpret your biopsy findings and personal risks.